

H. g K. g E cha ge, a d C ea i g Li i ed a d The S ck E cha ge .f H. g K. g  
Li i ed t ake . e . . i b i i f . t h e c . t e t , f t h i , a . . . c e e t , a k e .  
e r e e t a i . a t . i . a c c . a c . c . i e e e , a d e i e , d i c a i a i a b i i  
h a . . e e f . a . . . h . . . e e a i i g f . . i e i a c e . . t h e h . e . a  
i a t . f t h e c . t e t , f t h i , a . . . c e e t .



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**INSIDE INFORMATION ANNOUNCEMENT**  
**COMMENCEMENT OF INDEPENDENT**  
**THIRD PARTY INVESTIGATION**

T a a c e , e . . . a d e b S e e H e a k P a , a c e . a G . C . , L d . ( e  
**Company** ) . . . a . . . e I d e I f , a . P . . . I d e P a X I V A f e  
S e . e a d F . e O d . a c e ( C a e 5 7 1 f e L a . f H . K . ) a d R e  
1 3 . 0 9 ( 2 ) ( a ) f e R e G e . . . e L . . . f S e . e T e S c k E c a . f  
H . K . L , e d .

**FORMATION OF SPECIAL INVESTIGATION GROUP**

R e f e a e , a d e . e c d e d c e d e . e d e f , a a c e , e f  
e C , a d a e d 1 5 J a a 2 0 2 4 ( e **Incident** ) . A f e d a e f  
a c e , e , e C , a a e a b e d a d e e d e d - a e a  
( e **Special Investigation Group** ) c d c a c , e e e e a  
e I c d e .

T e S e c a I e . G . . e d b d e e d e . e e c . e d e c . f e  
C , a a d a e . e d a e a d . e a . a f e c e . a e a  
c d c e e a c a b a . a e d e a a a f . T e  
S e c a I e . G . . e e d c a I T d a a e c e a d e e a ,  
d c , e e , k e . e e e , e a c . e . e . , a d c , b e  
e . c e e a a a d . e c a e f . a e . e b a c e a d  
, a c f e I c d e . I . . c , e e e e e e a . e a d  
e a k e e . e e a c . f e C , a ' b d a e , e e c a . e  
e e a b d a e . T e S e c a I e . G . . a c e a e f a . ,  
e e e e e c e f e I c d e , c a f e e e a e b . e , a d e a e a  
d e e d e e f c a e . e . e C , a ' b a d f d e c . ( e  
**Board** ) a e a e b c a f e C , a ' 2 0 2 3 a a e . T e e  
a b e b e d f e f , a f e a e . f e C , a  
a e .

add the above Section 10(b) of the Securities Exchange Act of 1934, the Company is hereby notified that the Commission is conducting an investigation of the facts and circumstances surrounding the above-referenced matters. The Commission is currently reviewing the information provided to it and may request additional information from the Company. The Commission is also conducting an investigation of the facts and circumstances surrounding the above-referenced matters. The Commission is currently reviewing the information provided to it and may request additional information from the Company. The Commission is also conducting an investigation of the facts and circumstances surrounding the above-referenced matters. The Commission is currently reviewing the information provided to it and may request additional information from the Company.

The Company is currently conducting an investigation of the facts and circumstances surrounding the above-referenced matters. The Commission is currently reviewing the information provided to it and may request additional information from the Company.

**Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

B e n e B a d  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
January 30, 2024

*At the date of this announcement, the executive directors of the Company are M. Li Li, M. Li Ta, M. Sha Ya and M. Zha g Pi g; and the independent non-executive directors of the Company are D. L. Ch a, M. H a g P e g a d M. Yi Mi g.*